The slip
PARKINSON RECEIPTno. 5607
21 Oct 2026, 18:50 UTColigodendrocytes, braak
predictionGRM7 in oligodendrocytes tracks Braak Lewy-body stage
registered1548f924f285b910
discovery+0.56 p=0.118 n=9
replication-0.04 p=0.927 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.56, p 0.118)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT0cbe26e46c865a800992950b…
follows a8c67d5edd12…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 5607: GRM7 in oligodendrocytes, braak
- power
- full sample +0.25 (p 0.319, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.25 (p 0.319, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.22 (p 0.389, n 18). could be the mix.
- skeptic
- leave-one-out range +0.16 to +0.40, sign flips 0; without severely affected donors +0.25 (p 0.319, n 18). fragile.
- cell type
- strongest in OPCs: +0.65 (p 0.0036, n 18) vs +0.25 in oligodendrocytes. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GRM7 in oligodendrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GRM7 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.50 p 0.076 (needs p < 3.5e-4)